Oxford Biomedica PLC Licence & Supply Agreement with New Partner (5150Y)

TIDMOXB

RNS Number : 5150Y

Oxford Biomedica PLC

07 September 2022

Oxford Biomedica signs Licence & Supply Agreement with new partner for LentiVector(R) platform for late-stage clinical programme

Oxford, UK - 7 September 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement ("LSA") with an undisclosed US-based late-stage cell and gene therapy company. The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica's LentiVector(R) platform for its application in their lead programme, a cell-based therapy targeting a rare indication, putting into place a five-year clinical supply arrangement.

Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of drug product sold that utilises Oxford Biomedica's LentiVector(R) platform.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: "This partnership further demonstrates Oxford Biomedica's world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year. We look forward to continuing to build upon our position as a partner of choice to deliver life-saving cell and gene therapies to patients."

-Ends-

Enquiries:

Oxford Biomedica plc: T: [phone] / E: [e-mail]

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, VP, Corporate Affairs & Investor Relations

Consilium Strategic Communications:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Matthew Neal / Matthew Cole

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSSUESMEESEFU

(END) Dow Jones Newswires

September 07, 2022 02:00 ET (06:00 GMT)